KALA BIO, Inc. financial data

Symbol
KALA on Nasdaq
Location
Arlington, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 19 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 177% % -48%
Debt-to-equity 2572% % 370%
Return On Equity -2324% % -418%
Return On Assets -87% % -25%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,209,725 shares
Common Stock, Shares, Outstanding 7,432,925 shares 61%
Entity Public Float $23,900,000 USD -30%
Common Stock, Value, Issued $7,000 USD 40%
Weighted Average Number of Shares Outstanding, Basic 7,042,457 shares 52%
Weighted Average Number of Shares Outstanding, Diluted 7,042,457 shares 52%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $6,127,000 USD 19%
General and Administrative Expense $17,971,000 USD -4.2%
Operating Income (Loss) $38,395,000 USD 6.7%
Nonoperating Income (Expense) $2,554,000 USD 17%
Net Income (Loss) Attributable to Parent $35,841,000 USD 8%
Earnings Per Share, Basic -5 USD/shares 57%
Earnings Per Share, Diluted -5 USD/shares 57%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $21,096,000 USD -57%
Assets, Current $24,274,000 USD -53%
Property, Plant and Equipment, Net $603,000 USD -21%
Operating Lease, Right-of-Use Asset $1,507,000 USD -19%
Assets $25,021,000 USD -54%
Accounts Payable, Current $917,000 USD 29%
Employee-related Liabilities, Current $443,000 USD -43%
Accrued Liabilities, Current $4,497,000 USD -28%
Liabilities, Current $32,574,000 USD 36%
Operating Lease, Liability, Noncurrent $1,112,000 USD -27%
Liabilities $33,686,000 USD -29%
Retained Earnings (Accumulated Deficit) $695,586,000 USD -5.4%
Stockholders' Equity Attributable to Parent $8,665,000 USD -226%
Liabilities and Equity $25,021,000 USD -54%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $16,558,000 USD
Net Cash Provided by (Used in) Financing Activities $135,000 USD -102%
Net Cash Provided by (Used in) Investing Activities $13,000 USD 88%
Common Stock, Shares Authorized 120,000,000 shares 0%
Common Stock, Shares, Issued 7,432,925 shares 61%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $8,959,000 USD -271%
Interest Paid, Excluding Capitalized Interest, Operating Activities $909,000 USD -21%
Deferred Tax Assets, Valuation Allowance $139,507,000 USD 8.4%
Deferred Tax Assets, Gross $140,006,000 USD 8.2%
Operating Lease, Liability $1,532,000 USD -19%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $35,841,000 USD 8%
Property, Plant and Equipment, Gross $2,063,000 USD 11%
Operating Lease, Liability, Current $420,000 USD 14%
Lessee, Operating Lease, Liability, to be Paid, Year Two $644,000 USD 3.5%
Lessee, Operating Lease, Liability, to be Paid, Year One $622,000 USD 3.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $327,000 USD -41%
Lessee, Operating Lease, Liability, to be Paid, Year Three $440,000 USD -32%
Deferred Tax Assets, Operating Loss Carryforwards $121,135,000 USD 11%
Preferred Stock, Shares Authorized 5,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four $440,000 USD -32%
Operating Lease, Payments $596,000 USD 3.7%
Additional Paid in Capital $686,914,000 USD 3%
Depreciation, Depletion and Amortization $68,000 USD 3%
Share-based Payment Arrangement, Expense $8,688,000 USD 0.22%
Interest Expense $5,795,000 USD -14%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%